UPMC Physician Resources
Transcatheter Aortic Valve Replacement Program
Historically, treatment options for patients with severe aortic stenosis have been limited to surgical valve replacement and medical therapy. Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation (TAVI), is a less invasive approach that allows for aortic valve implantation for patients with severe aortic stenosis who are at increased surgical risk of have been turned down for traditional aortic valve replacement because of age or other medical conditions.
Since many patients with severe aortic stenosis are at high surgical risk and have considerable mortality in the short term, TAVR may provide a treatment pathway that would otherwise be unavailable. Unfortunately, the proportion of our patients that are less-than-ideal surgical candidates only continues to increase. Although not without risks, transcatheter aortic valve replacement is a promising alternative for this population, and we are fortunate to be able to provide patients with potential access to this option.
We're also among an exclusive group of hospitals with experience in these and other clinical trials:
- The Medtronic CoreValve Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) clinical trial for intermediate risk patients.
- The Medtronic CoreValve EvolutTM R System clinical trial for high or extreme risk patients.
- The Medtronic CoreValve® System clinical trial for very high risk patients.
For More Information or to refer a patient
Please call the UPMC Center for Aortic Valve Disease at 412-647-1621 or email ValveCenter@upmc.edu. We also are available to discuss the benefits of this procedure for your specific patients.